Prediction of Sustained Virological Response to Telaprevir/Simeprevir-Based Triple Therapy in Patients with Genotype 1 Hepatitis C Virus Using Super-Early Viral Response within 2 Weeks

Yoshinori Ozono¹, Yuka Takaishi¹, Mai Tsuchimochi², Kenichi Nakamura¹, Hiroo Abe¹, Tadashi Miike¹, Kazunori Kusumoto³, Hisayoshi Iwakiri¹, Mitsue Sueta⁴, Yoshihiro Tahara¹, Shojiro Yamamoto¹, Satoru Hasuike¹, Kenji Nagata^2* and Kazuya Shimoda^1,2,4

¹Department of Gastoroenterology and Hematology, Faculty of Medicine, University of Miyazaki, Miyazaki, Japan

²Department of Liver disease, University of Miyazaki Hospital, Miyazaki, Japan

³Department of Internal Medicine, Koga General Hospital, Miyazaki, Japan

⁴Oncology Unit, University of Miyazaki Hospital, Faculty of Medicine, University of Miyazaki, Miyazaki, Japan